

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

REGENERON PHARMACEUTICALS, INC.,  
Petitioner

v.

NOVARTIS PHARMA AG,  
NOVARTIS TECHNOLOGY LLC,  
NOVARTIS PHARMACEUTICALS CORPORATION,  
Patent Owners

---

Case IPR2021-00816  
Patent 9,220,631

---

**JOINT STIPULATION TO MODIFY  
DATE TO SERVE DEMONSTRATIVES ON  
OPPOSING COUNSEL**

Pursuant to Order Setting Oral Argument (Paper 99, entered on June 27, 2022), Patent Owners Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation (collectively, “Novartis”) and Petitioner Regeneron Pharmaceuticals, Inc. (“Regeneron”) (Regeneron and Novartis, collectively, “Parties”) respectfully request that the Board accept the Parties’ stipulation to modify the date of service of demonstratives on opposing counsel from July 12, 2022, to July 14, 2022. Paper 99 at 3 n.6.

This stipulation does not affect or otherwise modify the dates for any other deadlines in the Schedule Order (Paper 14) or Order Setting Oral Argument (Paper 99).

Dated: July 6, 2022

By: /Elizabeth J. Holland/  
Elizabeth J. Holland (Reg. No. 47,657)  
Lead Counsel for Patent Owners  
Allen & Overy LLP  
1221 Avenue of the Americas  
New York, NY 10020  
Phone: + 212 610 6365  
Elizabeth.Holland@allenoverly.com

By: /Anish R. Desai/  
Anish R. Desai (Reg. No. 73,760)  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8730  
anish.desai@weil.com

**CERTIFICATE OF SERVICE**

A copy of this **JOINT STIPULATION TO MODIFY DATE TO SERVE**

**DEMONSTRATIVES ON OPPOSING COUNSEL** has been served on

Petitioner's attorneys of record as follows via electronic mail:

Elizabeth Stotland Weiswasser  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8022  
F: 212-310-8007  
elizabeth.weiswasser@weil.com  
USPTO Reg. No. 55,721

Anish R. Desai  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8730  
F: 212-310-8007  
anish.desai@weil.com  
USPTO Reg. No. 73,760

Natalie Kennedy  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8730  
F: 212-310-8007  
natalie.kennedy@weil.com  
USPTO Reg. No. 68,511

Andrew Gesior  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8730  
F: 212-310-8007  
andrew.gesior@weil.com  
USPTO Reg. No. 76,588

Brian E. Ferguson  
Weil, Gotshal & Manges LLP  
2001 M Street, N.W., Suite 600  
Washington, D.C. 20036  
T: 202-682-7000  
F: 202-857-0940  
brian.ferguson@weil.com  
USPTO Reg. No. 36,801

Christopher M. Pepe  
Weil, Gotshal & Manges LLP  
2001 M Street, N.W., Suite 600  
Washington, D.C. 20036  
T: 202-682-7000  
F: 202-857-0940  
christopher.pepe@weil.com  
USPTO Reg. No. 73,851

Regeneron.IPR.Service@weil.com

***Attorneys for Regeneron Pharmaceuticals, Inc.***

Dated: July 6, 2022

By: /Frank ReDavid/  
Frank ReDavid  
Litigation Specialist  
Allen & Overy, LLP